By Monica Heger

In the race to develop the first sequencing-based trisomy 21 test, researchers from GATC Biotech subsidiary LifeCodexx said that they have completed a pilot study in 45 patients and plan to start a clinical validation study in 500 patients.

If all goes well, LifeCodexx could launch the test commercially by the end of the year, the company's CEO Michael Lutz told Clinical Sequencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.